Table 2.
Potential therapeutic usage of allosteric and biased GPCR signaling compounds/drugs.
| Receptors | Drugs | Indications | Reference |
|---|---|---|---|
| Calcium-sensing receptor (CaSR) | Cinacalcet (marketed) | Hyperparathyroidism | Goodman et al. (63) |
| C–C chemokine receptor type 5 (CCR5) | Maraviroc (marketed) | AIDS/HIV | Fätkenheuer et al. (61) |
| C–X–C chemokine receptor type 1/2 (CXCR1/2) | Reparixin | Reperfusion injury in lung and kidney transplantation | Bertini et al. (59), Zarbock et al. (64) |
| Prostaglandin F receptor (FP) | PDC31 (THG113.3) | Preterm labor and primary dysmenorrheal | Olson and Ammann (62); (http://clinicaltrials.gov/show/NCT01250587) |
| Metabotropic glutamate receptor 2 (mGluR2) | ADX71149 | Schizophrenia | Hashimoto et al. (65) |
| Metabotropic glutamate receptor 2/3 (mGluR2/3) | AZD8529 | Schizophrenia | (http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00985933) |
| Metabotropic glutamate receptor 5 (mGluR5) | AFQ056 | Parkinson’s disease levodopa-induced dyskinesia and fragile X syndrome | Berg et al. (66), Jacquemont et al. (67) |
| Dipraglurant (ADX48621) | Parkinson’s disease levodopa-induced dyskinesia and dystonia | Stocchi et al. (68); (http://www.addextherapeutics.com/rd/pipeline/dipra-ir/) | |
| ADX10059 | Gastro-esophageal reflux | Zerbib et al. (57); Stocchi et al. (68) | |
| RO4917523 | Depression and fragile X | http://clinicaltrials.gov/ct2/show/study/NCT01517698 | |
| Fenobam | Fragile X | Berry-Kravis et al. (69) | |
| STX107 | Fragile X and autism | http://clinicaltrials.gov/show/NCT01325740 |